Stock Analiz

MRK vs PFE stock comparison

Merck & Co. vs. Pfizer · data as of November 13, 2026

Merck & Co. (MRK) has a market value of about $364.3B, Pfizer (PFE) about $164.7B. Over their latest twelve months Merck & Co. had revenue of $67.4B and Pfizer $63.6B.

On our five checks Merck & Co. scores higher: 2.8 out of 5 (average) against 2.2 (weak).

By area, the stronger company is Pfizer on value; Merck & Co. on track record; Merck & Co. on shareholder returns.

Pfizer is cheaper on earnings (P/E 41.3 vs. 150.8), while Merck & Co. grew revenue faster over five years (9.4% vs. 8.5% a year).

Merck & Co. leads on 12 of the compared lines and Pfizer on 10.

Side by side

MRKPFE
Size and price
Market cap$364.3B$164.7B
Share price$147.76$28.89
Score
Overall score (of 5)2.82.2
Value01
Future growth22
Track record52
Financial health22
Shareholder returns54
Valuation
P/E (TTM)150.841.3
Forward P/E17.610.1
Price / free cash flow24.714.0
Price / sales5.42.6
EV / EBITDA32.516.1
PEG7.10—
DCF value vs. price−31%−31%
Business
Revenue$67.4B$63.6B
Net income$2.5B$4.0B
Free cash flow$14.7B$11.8B
Net margin3.6%6.3%
Gross margin (5-yr avg.)73.4%66.5%
ROIC (5-yr avg.)16.3%11.4%
Growth
Revenue growth (1 yr)1.3%-1.7%
Revenue growth (5 yrs, per year)9.4%8.5%
EPS growth (5 yrs, per year)21.2%-3.6%
Balance sheet and payouts
Net cash (cash minus debt)-$44.1B-$51.7B
Dividend yield2.30%5.95%
Shareholder yield3.7%5.9%
Analysts
Upside to average target+9%+5%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: MRK TTM to September 30, 2026, PFE TTM to September 27, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Merck & Co. or Pfizer?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and Pfizer 2.2; the table shows where each one is stronger.

Is Merck & Co. cheaper than Pfizer?

On trailing earnings, Pfizer trades at a P/E of 41.3 and Merck & Co. at 150.8, so Pfizer is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Merck & Co. or Pfizer?

Over five years Merck & Co. grew revenue about 9.4% a year and Pfizer about 8.5% a year.

Which pays a higher dividend?

Merck & Co. yields 2.30% and Pfizer 5.95%.

Full Merck & Co. analysis → Full Pfizer analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.